New Launch28 Nov 2024, 02:09 pm
Dr. Reddy's Launches First Immuno-Oncology Drug Toripalimab in India for Nasopharyngeal Carcinoma Treatment
AI Summary
Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India, a next generation PD-1 inhibitor approved for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). The combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death. India becomes the third country in the world to receive access to this New Biological Entity (NBE) after China and the United States.
Key Highlights
- Dr. Reddy's launched Toripalimab, the first and only immuno-oncology drug approved for the treatment of RM-NPC in India.
- Toripalimab is approved by various regulatory authorities around the world such as USFDA, DCGI, EMA, MHRA, NMPA and others.
- The combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death.
- India becomes the third country in the world to receive access to this New Biological Entity (NBE) after China and the United States.
- Dr. Reddy's will market Toripalimab under the brand name Zytorvi® in India.